Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine

被引:89
|
作者
Gilazieva, Zarema [1 ]
Ponomarev, Aleksei [1 ]
Rutland, Catrin [2 ]
Rizvanov, Albert [1 ]
Solovyeva, Valeriya [1 ]
机构
[1] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan 420008, Russia
[2] Univ Nottingham, Fac Med & Hlth Sci, Nottingham NG7 2UH, England
基金
俄罗斯科学基金会;
关键词
3D tumor models; spheroids; organoids; personalized medicine; oncological diseases; drug screening; biobank; BREAST-CANCER CELLS; IN-VITRO MODEL; LIQUID OVERLAY TECHNIQUE; STEM-CELL; OVARIAN-CANCER; CULTURE-SYSTEM; DRUG; 3D; GENERATION; GROWTH;
D O I
10.3390/cancers12102727
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Presently, the investigation of the tumor is carried out using different models. One of the promising areas is the creation of 3D tumor models, such as spheroids and organoids. These models are close in properties and organization to a native tumor. This review includes information about 3D tumor models, their differences, and methods for creating spheroids and organoids. The technical aspects of these models are summarized in this review. It provides an overview of the main uses of these models in personalized medicine to create a promising screening model for therapeutic agents and describes the latest research in this area. The combination of 3D tumor models and high-throughput approaches of personalized medicine (transcriptome, genomic, metabolomic, etc.) will open up new possibilities for the creation of improved therapy for oncological diseases. One of the promising directions in personalized medicine is the use of three-dimensional (3D) tumor models such as spheroids and organoids. Spheroids and organoids are three-dimensional cultures of tumor cells that can be obtained from patient tissue and, using high-throughput personalized medicine methods, provide a suitable therapy for that patient. These 3D models can be obtained from most types of tumors, which provides opportunities for the creation of biobanks with appropriate patient materials that can be used to screen drugs and facilitate the development of therapeutic agents. It should be noted that the use of spheroids and organoids would expand the understanding of tumor biology and its microenvironment, help develop new in vitro platforms for drug testing and create new therapeutic strategies. In this review, we discuss 3D tumor spheroid and organoid models, their advantages and disadvantages, and evaluate their promising use in personalized medicine.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 50 条
  • [41] Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment
    Zhao, Hongda
    Lin, Na
    Ho, Vincy Wing Sze
    Liu, Kang
    Chen, Xuan
    Wu, Hongwei
    Chiu, Peter Ka-Fung
    Huang, Linda
    Dantes, Zahra
    Wong, Ka-Leung
    Chau, Ho-Fai
    Ko, Ivan Ching-Ho
    Wong, Chris Ho-Ming
    Leung, David Ka-Wai
    Yuen, Steffi Kar-Kei
    Wu, Dinglan
    Ding, Xiaofan
    Ng, Chi Fai
    Teoh, Jeremy Yuen-Chun
    ADVANCED SCIENCE, 2025,
  • [42] Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling
    Vasyutin, Igor
    Zerihun, Lillian
    Ivan, Cristina
    Atala, Anthony
    ANTICANCER RESEARCH, 2019, 39 (03) : 1105 - 1118
  • [43] Engineered hydrogel microspheres for spheroids and organoids construction
    Gai, Tingting
    Zhang, Yuanwei
    Li, Guangfeng
    Zhou, Fengjin
    He, Chongru
    Wang, Xiuhui
    Su, Jiacan
    CHEMICAL ENGINEERING JOURNAL, 2024, 498
  • [44] Progress in The Research of Organoids and Applications
    Li Tian-Rui
    Zhao Rui-Bo
    Zhang Quan
    Kong Xiang-Dong
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2019, 46 (08) : 737 - 750
  • [45] Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
    Faria, Carla
    Gava, Fabien
    Gravelle, Pauline
    Valero, Juan Garcia
    Dobano-Lopez, Celia
    Van Acker, Nathalie
    Quelen, Cathy
    Jalowicki, Gael
    Morin, Renaud
    Rossi, Cedric
    Lagarde, Jean-Michel
    Fournie, Jean-Jacques
    Ysebaert, Loic
    Laurent, Camille
    Perez-Galan, Patricia
    Bezombes, Christine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [46] Engineered organoids for biomedical applications
    de Barros, Natan Roberto
    Wang, Canran
    Maity, Surjendu
    Peirsman, Arne
    Nasiri, Rohollah
    Herland, Anna
    Ermis, Menekse
    Kawakita, Satoru
    Carvalho, Bruna Gregatti
    Kouchehbaghi, Negar Hosseinzadeh
    Herculano, Rondinelli Donizetti
    Tirpakova, Zuzana
    Dabiri, Seyed Mohammad Hossein
    Tanaka, Jean Lucas
    Falcone, Natashya
    Choroomi, Auveen
    Chen, Runrun
    Huang, Shuyi
    Zisblatt, Elisheva
    Huang, Yixuan
    Rashad, Ahmad
    Khorsandi, Danial
    Gangrade, Ankit
    Voskanian, Leon
    Zhu, Yangzhi
    Li, Bingbing
    Akbarij, Mohsen
    Leem, Junmin
    Dokmeci, Mehmet Remzi
    Kim, Han-Jun
    Khademhosseini, Ali
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 203
  • [47] Tumor Oxygen Measurements and Personalized Medicine
    Okunieff, Paul
    O'Dell, Walter
    Zhang, Mei
    Zhang, Lurong
    Maguire, David
    OXYGEN TRANSPORT TO TISSUE XXXIV, 2013, 765 : 195 - 201
  • [48] Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation
    Soto-Gamez, Abel
    Gunawan, Jeremy P.
    Barazzuol, Lara
    Pringle, Sarah
    Coppes, Rob P.
    STEM CELLS, 2024, 42 (06) : 499 - 508
  • [49] Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine
    Tellez-Gabriel, Marta
    Cochonneau, Denis
    Cade, Marie
    Jubelin, Camille
    Heymann, Marie-Francoise
    Heymann, Dominique
    CANCERS, 2019, 11 (01):
  • [50] Personalized Medicine in Psoriasis: Concept and Applications
    Al-Hoqail, Ibrahim A.
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (03) : 432 - 436